Jubilant Pharmova Ltd.

NSE: JUBLPHARMA · Healthcare

₹1,060.45

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bearish 62% confidence

Overbought momentum (RSI 70.43) on weak volume (56% of average) masks a 45% profit collapse in Q1 FY27; operational recovery is unproven…

Strongest bull point

FY26 revenue grew 14% with CDMO Sterile Injectables surging 38%, and management has flagged temporary, quantified headwinds (~USD 14M SPECT impact in H1 FY27) with expected H2 recovery, supporting a transition-year thesis.

Strongest bear point

Q1 FY27 net profit collapsed 45% YoY despite 18% revenue growth; stock is overbought (RSI 70.43) on weak volume (56% of average) with price extended 6.4% above EMA-20, creating mean-reversion risk toward ₹1,007–₹972 if operational recovery fails to materialize.

Technical Forecast · next 10 trading days

Expected

₹978.90 -7.7%

Range

₹978.78 – ₹979.65

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on JUBLPHARMA, misses included

Bearish 28 Sep 2026 → now Scores 28 Oct 2026

₹1,060.45 → ₹1,060.45 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare